Многоцентровое, сравнительное исследование эффективности и безопасности симбикорта турбухалер по сравнению с рутинной противоастматической терапией у больных с стабильным течением бронхиальной астмы

Combined administration of long-acting [32-agonists and inhaled glucocorticosteroids is a modern standard of long-term therapy for bronchial asthma (BA). From this point of view combined drugs such as Symbicort (budesonide+formoterol) appear to be the most perspective. The aim of this study was to assess clinical efficacy of Symbicort compared with usual therapy given to BA patients in Moscow policlinics. Methods: this multi-center comparative trial with retrospective control involved 329 BA patients aged 10 to 75 years observed in 53 policlinics of Moscow and Moscow region. The patients received Symbicort 320/9 to 640/18 meg daily. The efficacy of the treatment was evaluated by peak expiratory flow rate (PEF), control for the disease signs (using the ACQ scale), seeking for medical care and quality of life. Conclusion: Symbicort allows to reduce the symptom s intensity, better control the disease, to increase PEF values, to decrease the need of bronchodilators and to improve the quality of life in patients with stable BA of various severity compared with usual BA treatment. According to the results Symbicort is more effective than the usual therapy generally given to BA adults and children in Moscow.